Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

China Medical System Holdings Limited

Healthcare US CHSYF

NoneUSD
0.00(0%)

Last update at 2026-04-30T21:01:29.835486Z

Day Range

--
LowHigh

52 Week Range

0.931.64
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap2270.47M
  • VolumeNone
  • P/E Ratio9.31
  • Dividend Yield21.63%
  • EBITDA1824.82M
  • Revenue TTM8212.06M
  • Revenue Per Share TTM3.39
  • Gross Profit TTM 5871.54M
  • Diluted EPS TTM0.10

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 2048.79M 2010.31M 2873.77M 3762.85M 3456.59M
Minority interest 45.62M 6.71M 16.51M -17.20300M -7.86200M
Net income 1450.47M 1619.79M 2400.94M 3258.99M 3017.40M
Selling general administrative 3708.03M 780.09M 656.63M 636.61M 441.00M
Selling and marketing expenses - 2661.65M 2511.34M 2721.31M 2540.15M
Gross profit 5720.02M 5422.19M 6075.95M 7035.85M 6246.94M
Reconciled depreciation 266.93M 259.24M 229.56M 227.23M 219.82M
Ebit 1537.75M 2048.92M 2712.85M 3622.44M 3377.56M
Ebitda 1797.79M 2308.16M 2922.15M 3849.67M 3597.38M
Depreciation and amortization 260.04M 259.24M 209.30M 227.23M 219.82M
Non operating income net other - - - - -
Operating income 1537.75M 1732.51M 2712.85M 3622.44M 3377.56M
Other operating expenses 6462.39M 5736.48M 5300.44M 5504.79M 5121.09M
Interest expense 19.77M 38.61M 46.25M 49.09M 28.27M
Tax provision 659.78M 397.23M 489.34M 486.65M 431.32M
Interest income 82.35M 126.34M 146.47M 105.52M 81.85M
Net interest income 62.05M 87.73M 100.22M 56.43M 53.58M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 642.76M 397.23M 489.34M 486.65M 431.32M
Total revenue 8000.14M 7468.99M 8013.28M 9150.35M 8337.22M
Total operating expenses 4182.27M 3689.68M 3363.10M 3390.29M 3030.81M
Cost of revenue 2280.12M 2046.80M 1937.33M 2114.50M 2090.28M
Total other income expense net 511.04M 277.79M 160.92M 140.41M 79.03M
Discontinued operations - - - - -
Net income from continuing ops 1443.28M 1613.08M 2384.43M 3276.20M 3025.26M
Net income applicable to common shares - - - 3258.99M 3017.40M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 19208.55M 18047.79M 17730.84M 17753.54M 15807.88M
Intangible assets 3696.30M 3490.60M 2216.09M 3351.84M 3006.18M
Earning assets - - - - -
Other current assets 261.36M 210.17M 149.72M 253.77M 213.12M
Total liab 1656.93M 1644.68M 2174.43M 3016.46M 2960.89M
Total stockholder equity 17404.52M 16311.47M 15520.21M 14589.07M 12752.44M
Deferred long term liab - - - - -
Other current liab 682.45M 331.56M 305.05M 899.95M 814.67M
Common stock 83.61M 83.56M 83.99M 83.99M 84.18M
Capital stock 83.56M 83.56M 83.99M 83.99M 84.18M
Retained earnings 14738.72M 13959.01M 13425.96M - 10550.09M
Other liab - - - 125.87M 286.06M
Good will 1512.02M 1547.90M 1547.90M 1665.99M 1691.18M
Other assets 0.00001M - - 1354.42M 903.66M
Cash 2702.74M 3706.50M 4311.06M 4376.38M 3385.74M
Cash and equivalents - - - - -
Total current liabilities 1469.97M 1516.06M 2048.79M 2877.10M 2081.25M
Current deferred revenue 12.14M - 17.23M 898.95M 812.67M
Net debt -2012.31695M -2845.75800M -3009.32100M -2563.74400M -1673.43400M
Short term debt 668.75M 848.23M 1285.07M 1799.14M 1120.68M
Short long term debt 651.82M 831.30M 1269.65M 1783.34M 1103.76M
Short long term debt total 690.43M 860.74M 1301.74M 1812.63M 1712.31M
Other stockholder equity 17320.92M 2268.90M 2297.61M 14505.08M 12668.27M
Property plant equipment - - - 495.46M 529.87M
Total current assets 9303.27M 8704.86M 8794.43M 8829.38M 7379.72M
Long term investments - - - - -
Net tangible assets - - - 10856.65M 8845.57M
Short term investments 3086.46M 2160.10M 1832.26M 1491.34M 977.87M
Net receivables 2448.34M 1859.95M 1863.76M 1442.04M 2330.38M
Long term debt - - - 0.00000M 573.81M
Inventory 804.36M 768.14M 637.64M 477.21M 472.60M
Accounts payable 106.63M 142.43M 141.66M 178.01M 145.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -287.35900M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00001M 2262.32M 2916.05M 3042.67M 2079.51M
Deferred long term asset charges - - - - -
Non current assets total 9905.29M 9342.93M 8936.40M 8924.16M 8428.16M
Capital lease obligations 38.26M 29.44M 32.09M 29.30M 34.73M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -693.81800M -615.09600M -442.27600M -1178.20200M -898.53500M
Change to liabilities - - - 0.00000M -24.55800M
Total cashflows from investing activities -984.32200M -615.09600M -442.27600M -1178.20200M -1519.52500M
Net borrowings -179.48500M -442.85000M -510.19300M - 1065.57M
Total cash from financing activities -770.93600M -1261.04600M -2125.02400M -1399.91400M -258.39200M
Change to operating activities - - - - -112.76500M
Net income 2103.06M 2010.31M 2873.77M 3762.85M 3456.59M
Change in cash -1005.12100M -604.55700M -65.31800M 990.64M 717.31M
Begin period cash flow 3706.50M 4311.06M 4376.38M 3385.74M 2668.43M
End period cash flow 2701.38M 3706.50M 4311.06M 4376.38M 3385.74M
Total cash from operating activities 758.42M 1268.55M 2502.85M 3553.24M 2493.85M
Issuance of capital stock - - - - -
Depreciation 266.93M 259.24M 229.56M 227.23M 219.82M
Other cashflows from investing activities -167.30100M -178.67800M 66.50M -554.70400M 126.64M
Dividends paid 660.55M 556.16M 1360.36M -1276.23900M -1154.83400M
Change to inventory -55.90500M -130.50300M -235.76700M 8.16M -90.86500M
Change to account receivables -611.16800M -49.34300M 410.56M - -367.88600M
Sale purchase of stock 0.00000M -238.39400M 0.00000M -48.38200M -151.51900M
Other cashflows from financing activities 69.10M -23.64000M -236.39900M 1352.70M 1047.97M
Change to netincome - - - 67.03M -147.29600M
Capital expenditures 514.41M 455.91M 317.96M 524.92M 184.84M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -648.78200M -128.14800M 2.97M 90.08M -596.07400M
Stock based compensation 27.31M 0.00000M -35.87200M 18.72M 17.16M
Other non cash items -990.09600M -872.85000M -567.58100M -545.62400M -603.63900M
Free cash flow 244.01M 812.64M 2184.89M 3028.32M 2309.01M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CHSYF
China Medical System Holdings Limited		 - -% - 9.31 7.94 0.28 1.38 3.09 11.87
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression. It also provides gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization; Salofalk for ulcerative colitis and Crohn's disease; Bioflor, a saccharomyces boulardii sachets for diarrhea; Combizym and Cidine for digestive enzymes; and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones. In addition, the company offers dermatology products, including ILUMETRI, a tildrakizumab injection for the treatment of plaque psoriasis; Aethoxysklerol, a polidocanol injection for sclerotherapy of various varicose veins; Hirudoid, a mucopolysaccharide polysulfate cream to treat blunt traumata; skin heling soothing product; and Hirudoid for acne-prone skin care, prevention, and enhancement of acne. Further, it provides Vmonalisa, modified sodium hyaluronate filler for mid to deep dermal implantation; augentropfen stulln mono eye drops for asthenopia; EyeOP1 glaucoma treatment device; and Elcitonin for Osteoporosis pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.

China Medical System Holdings Limited

Island Place Tower, North Point, Hong Kong

Key Executives

Name Title Year Born
Mr. Kong Lam Founder, Chairman, CEO & Pres 1965
Ms. Yanling Chen CFO, VP & Exec. Director 1970
Mr. Hongbing Chen COO, VP, Director of Sales & Marketing and Exec. Director 1967
Dr. Wai Ming Wong Chief Technical Officer 1961
Ms. Sanyan Wu Director of Legal Department & Company Sec. 1983
Dr. Kong Lam Founder, Chairman, CEO & President 1965
Ms. Yanling Chen CFO, VP & Executive Director 1970
Mr. Lieyi Ma General Manager of the Operations & Management Center of the Group 1970
Liu Yue Director of Investor Relations NA
Ms. Sanyan Wu Director of Legal Department & Company Secretary 1983

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions